1. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
   Luigi Formisano et al, 2015, Oncotarget CrossRef
2. Erlotinib has tumor inhibitory effect in human retinoblastoma cells
   Yi Shao et al, 2017, Biomedicine & Pharmacotherapy CrossRef
3. Integrin α1β1 protects against signs of post-traumatic osteoarthritis in the female murine knee partially via regulation of epidermal growth factor receptor signalling
   S.Y. Shin et al, 2016, Osteoarthritis and Cartilage CrossRef
4. Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells
   Carolina Torres et al, 2016, Pancreas CrossRef
5. NSCLC harboring EGFR exon‐20 insertions after the regulatory C‐helix of kinase domain responds poorly to known EGFR inhibitors
   Mengmeng Yang et al, 2016, International Journal of Cancer CrossRef
6. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
   Amir Hossein Daneshmanesh et al, 2018, PLOS ONE CrossRef
7. Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
   Koh Furugaki et al, 2014, Lung Cancer CrossRef
8. Erlotinib conjugated gold nanocluster enveloped magnetic iron oxide nanoparticles–A targeted probe for imaging pancreatic cancer cells
   John Nebu et al, 2018, Sensors and Actuators B: Chemical CrossRef
9. Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
   Koh Furugaki et al, 2011, Clinical & Experimental Metastasis CrossRef
10. Serum Metabolite Profiles Are Altered by Erlotinib Treatment and the Integrin α1-Null Genotype but Not by Post-Traumatic Osteoarthritis
    Beata Mickiewicz et al, 2016, Journal of Proteome Research CrossRef